

### DETAILED ACTION

The amendment filed on April 01, 2008 has been acknowledged. Claim 1 has been amended. Claims 2, 10 and 14-28 were canceled. Claims 1, 3-9, 11-13, 29-30 are pending and considered.

### EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Tamsen L. Barrett on June 30, 2008.

The application has been amended as follows:

Claim 1 (current amended). In line 1 after "response" please insert --- to an antigen --- In line 2 after "comprising" please delete "a peptide" and insert --- an isolated peptide consisting of an amino acid sequence, wherein the amino acid sequence is --- In line 4 after "comprising" please insert --- a heterologous ---

Claim 4 (current amended). In line 1 before "antigen", please delete "antigen comprises" and insert --- the heterologous antigen is ---

Claim 9 (current amended). In line 1 after "an immune response" and insert -- to an antigen ---

Claim 12(current amended). In line 1 before "antigen", please delete "antigen comprises" and insert --- the heterologous antigen is ---

Claims 1, 3-9, 11-13 and 29-30 are allowed.

2. The following is an examiner's statement of reasons for allowance: The amendment effectively overcomes all outstanding rejections made in the previous office action. No prior art teaches or suggests a composition comprising a particular peptide fused with another

SM  
7/21/08

SM  
7/21/08